AC Immune SA filed its Form 6-K for the nine months ended September 30, 2025, detailing significant financial deterioration driven by the non-recurrence of large milestone payments received in 2024.
Financial Results (9M 2025): Total revenue collapsed to CHF 3.2M (down from CHF 26.2M in 9M 2024), primarily due to zero revenue from the Janssen collaboration (which contributed CHF 24.6M in 2024). Consequently, the Net Loss widened to (CHF 56.1M) from (CHF 35.1M) in the prior year, resulting in a Basic/Diluted Loss per Share of (CHF 0.56). Q3 2025 saw a net loss of CHF 15.9M compared to a ne
...